Great to see you again, Stephen V Liu, MD! Appreciate all the inspiration and opportunities you’ve opened up. #ASCO25

Excited for the #LCSM session today at #ASCO25! 🚨 Here’s the latest treatment algorithm for advanced/metastatic #NSCLC 👇 How will it change after today?🔥 Can’t wait to see where new agents & trial data may fit in! LungCancerRx 🫁💊 Hem-Onc Fellows Network @Oncoalert Oncology Brothers

#ASCO25 Day 2: Let’s talk about lung 🫁 🔹 Education Session – 1L Dilemmas in EGFR+ mNSCLC Insightful debate between Julia Rotow MD and Alessio Cortellini on the daily mono vs. combo dilemma. I believe more patients deserve a grace period with TKI monotherapy—and we need real-time,

Full house at the #ASCO25 lung oral abstracts! Next year we may need the plenary hall for the lung orals

Question of the year #ASCO25 by the one and only Dr. Corey Langer of Penn: "When does statistical significance become clinically meaningless?" #LCSM 😁😅🤷‍♂️

Omg. I got a shout out from THE Mark Lewis, MD, FASCO on the plenary stage! This is my biggest honour. Thank you 🙏 #ASCO25

SNUH POLARIS is a newly launched precision medicine platform using advanced AI technologies, including Large Language Models (LLM), to combine clinical and genomic data.

A fun night connecting and making new friends at IASLC reception! #ASCO25 Wishing all the best on our PhD journeys🙏 Yuji Uehara, MD & Yunhuan Liu Can’t wait to reunite at #WCLC25 in Barcelona and #WCLC26 in Seoul!

#ASCO25 Day 3-4: It’s all about life🙌 Many positive #lungcancer trials were celebrated—but what stays with me are the deeply patient-centered conversations on what these results mean, including stellar talks on BiTE/AMI toxicities—financial, time, and beyond. It reminded me:

Press release, press release! OS-imertinib and chemo are making the oncology Jumbotron today- and with a very hot play on OS they have nothing to hide! With OS being the 🐘in the room and both MARIPOSA and FLAURA2 reaching this key endpoint- the pendulum has clearly swung in

Eric K. Singhi, MD Narjust Florez, MD, FASCO Edward S. Kim, MD, MBA, FACP, FASCO Xiuning Le MD PhD Who could have thought Checkmate trials would be attending Coldplay concerts??

⭐️This year has already seen MAJOR advances in #lungcancer therapies, especially for #EGFR #NSCLC, #SCLC, & the neoadjuvant space. 👇🏾With #WCLC25 around the corner, this is my personal list of the MOST EXCITING abstracts to be showcased this year & why I think they are great!

Kicking off a fantastic #WCLC25 IASLC in beautiful Barcelona🇪🇸! Who else is in the town? Let’s meet up😁 #LCSM

⭐️SCLC biomarkers Pleasantly surprised to see a fully packed room for the earliest Day 1 session at #WCLC25! Inspiring talks and energized crowd. With the 4 subtypes, novel targets (DLL3, B7-H3, SEZ6), and subtype-driven trials like S2409-PRISM, could #SCLC be the next adenoca?

The best part of #WCLC25? Catching up with old friends & making new ones! Great time with early-career colleagues 👍 Wishing the best on our journeys, Nina Steinmann Yunan Nie Huge congrats to my IM residency sister So Yeon (Lydia) Kim, MD, MS on joining the IASLC Academy👏 You deserve it!

IASLC - WCLC 2025 Recap 🔗 Explore more insights and data from #WCLC25: t.ly/awcNH #LARVOL #CancerResearch #Oncology #ClinicalTrials #LungCancer #WCLC2025 #IASLC #LCSM #NSCLC #SCLC | Hidehito HORINOUCHI | Diego A. Díaz-García | Stephen V Liu, MD | Eric K. Singhi, MD | Dr. Antonio Calles 🫁🚭 |

Back home from #WCLC25. It’s truly heartwarming to know we have brilliant minds and a strong community united in the fight against this unforgiving disease. Can’t wait to see you all in Seoul next year! Now, let’s get back to work and bring these new inspirations to life🤍 #LCSM